Centerpoint Advisory Group’s Bristol-Myers Squibb BMY Stock Holding History

Centerpoint Advisory Group’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,027	Closed	-$307K	–	102
2025 Q1	$307K	Hold	5,027	–	–	0.3%	73
2024 Q4	$284K	Buy	+5,027	New	+$281K	0.28%	73

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Centerpoint Advisory Group's BMY Position: Q2 2025 in Review

Centerpoint Advisory Group sold out of Bristol-Myers Squibb (BMY) in Q2 2025, closing a stake of 5,027 shares — an estimated $307K sold.

Centerpoint Advisory Group first reported a position in BMY in Q4 2024 and held it in 2 quarters. The position peaked at $307K in Q1 2025. 2,292 funds tracked by Wall St. Rank hold BMY as of Q2 2025.

Centerpoint Advisory Group reported no remaining Bristol-Myers Squibb position as of Q2 2025 after selling out during the quarter.
Centerpoint Advisory Group sold 5,027 Bristol-Myers Squibb shares in Q2 2025, an estimated $307K.
Centerpoint Advisory Group first reported a position in Bristol-Myers Squibb in Q4 2024 and held it in 2 quarters.
Centerpoint Advisory Group's Bristol-Myers Squibb position peaked at $307K in Q1 2025.
2,292 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.

Based on Centerpoint Advisory Group's 13F filing for Q2 2025, filed 6 Aug 2025.